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Purpose: Current hypertension guidelines stipulate that all incompatible medications be 
stopped before performing laboratory screening for aldosteronism, but patient adherence is 
unclear. We measured plasma drug concentrations to determine drug adherence and potential 
drug bias during biochemical tests.
Patients and methods: Plasma concentrations of 10 antihypertensive drugs were quantified 
by mass spectrometry in 24 consecutive ambulatory patients with uncontrolled hypertension 
routinely evaluated for aldosteronism. Drug screening was done before (first visit), and on the 
day of biochemical tests (second visit) after stopping all incompatible medications. Concentra-
tions above those expected at trough dosing interval defined same-day dose intake.
Results: On the first and second visits, 76% vs 77% of prescribed antihypertensive doses could 
be verified in plasma. A total of 33% of patients were found to be nonadherent and showed 
divergent plasma drug results relative to prescriptions (21% drugs not detected/13% unprescribed 
drugs found) on first visit, 25% on the second (0%/25%), and 46% for both. A total of 21% 
used medication incompatible with the biochemical tests on the second visit. Moreover, 17% of 
drug concentrations were below expected trough levels on the first vs 15% on the second visit. 
This analysis revealed additional four (17%) vs three (13%) nonadherent patients who failed 
same-day dose intake and remained undetected by qualitative drug tests.
Conclusion: Nonadherence was frequent during laboratory evaluations for aldosteronism advo-
cating cautious interpretation of results. A multicenter study is desirable to set the stage for new 
screening protocols that should incorporate also incentives and checks of drug adherence.
Keywords: adherence, drug, hypertension, screening, aldosterone, spectrometry
Introduction
Primary aldosteronism (PA) is a frequent and well-known cause of secondary 
hypertension with an estimated prevalence of 5% to 10% among unselected patients 
with high blood pressure (BP).1 Its diagnosis is demanding since plasma renin and 
aldosterone measurements necessitate standardized laboratory conditions. To avoid 
biased biochemical results and erroneous conclusions, guidelines stipulate that all 
drugs with a direct or indirect influence on the renin–angiotensin–aldosterone system 
(RAAS) should be paused sufficiently in advance before the recommended screen-
ing tests can be done.2–4 In daily practice, however, patients may not strictly adhere 
to prescribed drug regimens and the reliability of biochemical test results, therefore, 
remains unclear.5
Adherence to prescribed medication can be verified by pill counts, electronic 
dispensers, and standardized questionnaires, albeit without final proof of drug intake. 
Instead, drugs can also be measured directly in plasma by liquid chromatography-
tandem mass spectrometry (LC-MS/MS), which confirms actual drug use and 
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provides drug concentrations for useful pharmacokinetic 
evaluations.5,6 We relied on this novel technology to verify 
drug adherence during routine laboratory screening for PA 
and check for potential drug bias of the results.
In a pilot study, we measured plasma drug concentrations 
in routine patients screened for PA and relied on a neutral 
study setting to avoid alerting patients as to the study aim. 
We performed standard qualitative drug screening based on 
the detection of drugs in plasma and also applied pharma-
cokinetic concentration thresholds to confirm same-day dose 
intake. This should improve the detection of nonadherence 
due to irregular drug use.
Patients and methods
clinical protocol and study population
All new referrals at our hypertension clinic were routinely 
subjected to our standardized laboratory protocol for 
secondary hypertension and aldosteronism. On the first visit, 
clinical routine workup was done, prescribed drugs and doses 
were recorded, and blood samples for routine biochemistry 
were obtained between 9:00 am and 5:00 pm. Prescriptions 
listed in the referral letters were systematically checked for 
accuracy by interrogating patients, medication cards, the 
hospital’s electronic records system, and caregivers and 
family members as necessary. All drugs interfering with the 
RAAS or the sympathetic nervous system and incompatible 
with plasma renin and aldosterone measurements during 
PA screening were paused. These included angiotensin-
converting enzyme inhibitors, angiotensin or β-adrenergic 
receptor blockers, diuretics, and centrally acting sympatho-
lytic drugs. Only amlodipine (aml), lercanidipine (ler), and 
doxazosin were allowed to treat hypertension thereafter. 
New treatment plans were established and patients instructed 
accordingly. A second visit was scheduled 2–4 weeks later 
to allow for sufficient washout of drug concentrations after 
discontinuation. Plasma renin and aldosterone concentrations 
were then measured under standardized conditions. Patients 
were obliged to take their medication while fasting at 
6:30 am. All prescribed and used drugs were checked again 
for intercurrent changes during the visit. Blood samples for 
biochemical tests were taken between 8:30 and 9:30 am after 
1 hour supine rest.
To study drug adherence, we used first and second visit 
blood samples from patients who participated in a prospective 
observational study of new predictive biomarkers while being 
subjected to this protocol (NCT03034265). The inclusion 
criteria of this primary study were age $18 years, treat-
ment with $2 antihypertensive drugs for $3 months, and a 
mean office BP .140/90 mmHg on the first visit (mean of 
three readings with a semi-automated device). Prespecified 
exclusion criteria were pregnancy, chronic renal insufficiency 
grade $4, cardiac insufficiency New York Heart Associa-
tion grade IV, chronic obstructive lung disease grade $3, 
liver insufficiency CHILD grade B or C, drugs significantly 
interfering with the RAAS or sympathetic nervous activity 
that could not be paused between the two visits, treatment 
with aliskiren or a mineralocorticoid receptor antagonist, 
and a BP $180/100 mmHg on the first visit.7,8 Glomerular 
filtration rate was estimated using the chronic kidney disease 
epidemiology collaboration formula.9
All 54 new clinic referrals were screened over a 12-month 
period for participation in the primary study. Twenty-nine 
patients were eligible, presented no exclusion criteria, and 
were asked to participate. Of them, 25 patients agreed 
and were included on the first visit after providing written 
informed consent. One patient failed to attend the second visit 
and was excluded. Finally, 24 patients remained for analysis. 
One screened patient was on spironolactone and excluded 
whereas none was on aliskiren. Permission for the protocol 
was obtained from the local ethics board (Ethikkommission 
des Kantons Bern, BE/20/2016; primary data are with the cor-
responding author and available upon reasonable request).
Plasma drug assays
Plasma drug concentrations were quantitated by LC-MS/MS 
using a Shimadzu (Kyoto, Japan) high-pressure liquid chro-
matograph coupled to an API 4000 tandem mass spectrometer 
(AB Sciex, Concord, ON, Canada) and standard operating 
protocols.10 Drug assays were available for aml, ler, nebivolol 
(neb), metoprolol, bisoprolol, perindoprilat (per), valsartan 
(val), candesartan, olmesartan, irbesartan (irb), and hydro-
chlorothiazide. These drugs were assayed in all study patients 
and all blood samples from both visits under blinded condi-
tions. Corrected peak areas were used for quantitation after 
internal calibration with deuterated compounds. Calibration 
curves were generated using test plasma spiked with graded 
concentrations of the analytes. The lower limit of quantitation 
(LOQ) was 1.0 ng/mL except for ler and neb (0.25 ng/mL), 
per (0.5 ng/mL), val and irb (50 ng/mL). Coefficients of 
determination (r2) were .0.99. Within-day test accuracy 
ranged from 89% to 111%. Duplicate measurements were 
performed and mean values were calculated.
For each analyte, expected mean peak (C
max
) and 24-hour 
trough concentrations (C
min
) were extracted from the literature 
with respect to once daily intake, steady-state conditions, an 
estimated GFR .60 mL/min, and the daily doses used. Ratios 
of measured (C
x
) with expected peak concentrations (C
max
) 
were calculated for each drug (C
x
/C
max
). The results were 
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given as a precentage.11–23 For metoprolol (met), retarded 
galenics were considered.24 Intermediate doses or time 
points were extrapolated as necessary. A plasma drug test 
was regarded positive if results were $ LOQ. Nonadherence 
was defined as a plasma drug result not consistent with pre-
scriptions. Nonadherence due to missing drug intake (NMI) 
corresponded to a negative plasma result despite a prescrip-
tion. Conversely, if a drug was detected in plasma without 
a prescription, this was regarded as unprescribed drug use 
or self-medication. Partial NMI was defined, if one or more 
of prescribed and tested drugs were absent in plasma and 
complete NMI, if all tests were negative. Moreover, C
x
/C
max
 
values greater than C
min
/C
max
 expected for each drug and 
dose were accepted as same-day dose intake. Frequencies 
and percentages with 95% CIs were calculated, and mean 
values with SDs.
Results
Table 1 shows the characteristics of the study population, and 
the classes and frequencies of prescribed antihypertensives 
on each visit. Drugs were mostly taken as a single morning 
dose ($92%) and only exceptionally in two divided doses 
or as a single evening dose. The mean interval between the 
two visits was 15±6 days. On the first visit, all patients except 
one were on at least one antihypertensive drug classified as 
incompatible with the laboratory tests for aldosteronism. 
These drugs were subsequently stopped. On the second visit, 
no further medication changes were noted in all patients.
On the first visit, 18 different antihypertensive drugs 
were used vs three on the second and 79 vs 26 individual 
daily doses were prescribed (Table 2). Of these prescribed 
doses, 76% could be verified in plasma on the first vs 77% 
Table 1 Patient characteristics and prescribed medication on the 
first and second visits (mean ± sD); n=24
Age (years) 54±13  
Female (%) 42  
Body weight (kg) 82±22  
eGFR (mL/min/1.73 m2) 81±24  
Prescribed medication First visit second visit
number of pills taken, any reason 5.2±3.6 3.8±3.1
Antihypertensive drugs per patient 3.2±1.1 1.1±0.7
Number of antihypertensive pills/patient 2.5±1.0 1.1±0.7
ARB/ACE inhibitors (%) 83 0
β-blockers (%) 54 0
Ca-antagonists (%) 88 83
Diureticsa (%) 67 0
α-adrenoceptor blocker (%) 21 25
Moxonidine (%) 8 0
Note: aThiazide-like, amiloride, loop diuretics.
Abbreviations: Ace, angiotensin converting enzyme; ArB, angiotensin receptor 
blocker; eGFR, estimated glomerular filtration rate. T
ab
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on the second visit with 90.0% vs 100% confirmatory results. 
Moreover, systematic screening of all plasma samples 
resulted in three additional positive drug tests on the first and 
seven on the second visit without a corresponding prescrip-
tion. All three unexpected findings on the first and six on the 
second visit concerned drugs classified as incompatible with 
the planned laboratory tests.
The corresponding rates for nonadherence, missing 
drug intake, and unreported drug use are shown in Table 3. 
Nonadherence was detected in 33% of patients on the first 
visit, in 25% on the second visit, and in 46% for both visits 
combined. Nonadherence due to missing drug intake was 
present only on the first visit and partial while unreported 
drug use was less frequent. On the second (laboratory) visit, 
unexpected drug use without a prescription was detected in 
one of four patients. Drugs incompatible with the laboratory 
tests were used by five (21%): three (13%) did not stop these 
drugs appropriately after the first visit and two (8%) used 
such drugs without a prescription.
The plasma drug concentrations are shown in Figure 1. 
On the first visit, 59.2% were within ±50% of C
max
, 57% 
between C
max
 and C
min
, and 17% below C
min
. On the second 
visit, the corresponding rates were 78%, 35%, and 15%. 
Compared with qualitative drug screening (Table 3), four 
patients on the first (16.7%) and three on the second visit 
(12.5%) showed drug concentrations below C
min
/C
max
 and 
were additionally classified as nonadherent.
Discussion
As a main result, every second patient presented a mis-
match between prescriptions and qualitative plasma drug 
results on one of the two visits because of nonadherence. 
More importantly, every fifth patient used incompatible 
drugs during laboratory tests for PA unexpectedly without 
a prescription. One reason was failure to stop such drugs 
beforehand as required. Indeed, the true rates of nonadher-
ence and unreported drug use may have been even higher 
since a few prescribed drugs could not be verified in plasma. 
Figure 1 Plasma concentrations of antihypertensive drugs on the first and second visits expressed as ratios with expected peak concentrations (Cmax, 100%); logarithmic 
representation.
Notes: Only prescriptions confirmed in plasma are shown. Solid circles indicate results $expected cmin and empty circles indicate results ,expected cmin. expected mean 
cmax (highest/lowest daily dose) and Cmin values (% Cmax) were as follows: per 36.4/15.1 ng/mL (7%/5%); can 234 ng/mL (28%); irb 2,040 ng/mL (5%); olm 507 ng/mL (4%); val 
5,550/3,940 ng/mL (18%/3%); aml 17.5/10.5 ng/mL (79%/57%); ler 7.7/3.3 ng/mL (5%/1%); met 53.5/11.2 ng/mL (70%/24%); neb 1.5 ng/mL (7%); hct 260/70 ng/mL (14%/9%).
Abbreviations: aml, amlodipine; can, candesartan; hct, hydrochlorothiazide; irb, irbesartan; olm, olmesartan; per, perindopril; val, valsartan; ler, lercanidipine; met, 
metoprolol; neb, nebivolol. 
??
???
??????
??????????? ????????????
?
??? ??? ??? ?? ??? ??? ??? ??? ??? ????
??
???
?????
??? ???
? ??
?
Table 3 nonadherence and unreported drug use among study participants according to plasma drug screening
Parameter First visit Second visit
Patients on antihypertensives, n (%) 24 (100.0) 18 (75.0)
Nonadherence, n (%, 95%CI) 8 (33.3; 18.0–53.3) 6 (25.0; 12.0–44.9)
Missing intake, n (%, 95%CI)a 5 (20.8; 9.2–40.5) 0 (0; 0–13.8)
Unprescribed drug use, n (%, 95%CI)b 3 (12.5; 3.3–33.5) 6 (25.0; 12.0–44.9)
Notes: a$1 prescription not detected in plasma. b$1 drug detected in plasma without a corresponding prescription.
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Together, our survey suggests that in clinical routine practice, 
the validity of biochemical PA screening may often be ques-
tionable and results unreliable.
Nonadherence to prescribed medication may occur in 
10% to .50% of treated hypertensive patients and is usually 
only partial according to previous study evidence.5,6,25–30 
We relied on sensitive LC-MS/MS technology for plasma 
drug screening and found a comparable rate of 21% on the 
first study visit. We analyzed blood samples from a bio-
marker study, which gave us a relatively unbiased picture of 
drug adherence because it was not advertised as the principal 
study aim during patient recruitment. A survey of plasma 
drug levels in hypertensive patients at a US emergency 
department reported a nonadherence rate of 28%.27 Another 
study in a French hypertension clinic relied on urinary drug 
tests and found a much lower nonadherence rate of only 
10%. It increased with the number of prescribed drugs per 
patient and was also associated with a higher BP level.28 
The patients, however, were on long-term follow-up and 
their BP was at, or close to, the recommended target values 
which made frequent medication changes unnecessary. In 
contrast, our patients were new referrals with often various 
treatment changes in the past or an irregular follow-up. 
This readily explains the higher rate of nonadherence dur-
ing our study.
We also observed a significant rate of unreported drug 
use or self-medication. Data on self-medication are scarce for 
hypertensive patients.25–30 In one large survey, 38 different 
drugs were screened in 821 random serum samples by 
LC-MS/MS and 33% of positive hits did not correspond to a 
known prescription.31 In another study, 8.3% of hypertensive 
patients relied on some kind of self-medication according to 
plasma drug checks yet without reporting this to the clinic.30 
Indeed, the current review literature still neglects self-
medication as a relevant topic.5,32 Furthermore, adherence 
questionnaires do not query for potential self-medication 
and do not help to resolve this problem.6
Most unexpected plasma drug findings were 
β-adrenoceptor and RAAS blockers, which may hamper the 
diagnosis of PA by influencing renin and aldosterone secre-
tion and plasma levels.2–4 Our survey suggests that two out 
of ten patients or more may exhibit unreliable biochemical 
test results in clinical routine practice. Interestingly, current 
guidelines for the laboratory workup of aldosteronism do 
not mention nonadherence as a potential source of bias and 
a caveat.2–4 Cautious result interpretations and repeated tests 
in unclear situations are, therefore, advisable.
We also aimed to improve the detection of nonadher-
ence by analyzing plasma drug concentrations. LC-MS/MS 
methodology is highly sensitive. Qualitative drug screening 
based on LOQ thresholds may thus easily generate false 
positive results when drugs are slowly cleared from plasma 
and can be detected still days after discontinuation.5,10,25,26,29,30 
Using indexed plasma drug concentrations and expected 
C
min
 as a threshold for same-day drug intake, we addition-
ally revealed up to four nonadherent patients compared 
with only qualitative plasma drug screening. Drug concen-
trations in our study were generally around the expected 
C
max
 or within the therapeutic range, that is, between C
max
 
and C
min
. Investigating unselected serum samples, another 
study found just 40%–50% of drug concentrations within 
the expected therapeutic limits.31 A precise quantitative 
analysis of drug concentration may be of particular interest 
whenever drug adherence is critical to clinical outcomes or 
in research settings.
Some important limitations of our study need to be 
addressed specifically. As a pilot study in a small number of 
patients, our survey provided only preliminary results. They 
require undoubtedly further confirmation by a larger cohort 
and also in different clinical settings. A few drugs could not 
be tested in plasma while the true rates of nonadherence may 
have been possibly higher. Next, we investigated patients 
without major comorbidity. They probably had also a lower 
overall pill count than could be expected for the general 
population and possibly had also a lower propensity to omit 
medication.28 Our inclusion and exclusion criteria were 
narrow and plasma drug screening was only punctiform. 
Moreover, there may have been some “white coat effect” 
that transiently improved drug adherence during laboratory 
tests compared with the everyday situation. Depending on 
the clinical situation, nonadherence during laboratory workup 
for PA may thus be quite variable and difficult to predict. 
Nevertheless, we believe that our study conclusions remain 
generally valid despite these confounding factors.
Finally, our study did not address the question of how 
many patients would possibly be misclassified for PA 
because of incompatible drugs during the tests for which a 
larger study with confirmatory PA testing would be neces-
sary. Our protocol fulfilled guideline recommendations and 
represents current practice standards. We relied on oral 
instructions, written treatment plans, and a second medication 
check on the day of the crucial tests, which finally did not 
suffice to assure medication adherence and valid laboratory 
conditions in all patients. Additional measures, therefore, 
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appear necessary to improve overall drug adherence and 
concomitantly the reliability of biochemical test results. Edu-
cational and motivational checks, controlled drug dispensing, 
and plasma drug monitoring whenever possible may be useful 
in this context.5,32
Conclusion
Together, nonadherence to prescriptions was frequent during 
routine laboratory evaluations for PA. Cautious interpreta-
tion of laboratory findings and repeated testing in unclear 
situations are, therefore, advisable. In addition, extra safety 
measures, such as plasma drug screening should be consid-
ered to minimize the inherent risk of drug bias whenever pos-
sible. A larger multicenter survey is desirable to corroborate 
our findings and set the stage for new screening protocols 
that should incorporate also incentives and checks of drug 
adherence.
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